Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.

Fiche publication

Date publication

janvier 2025

Journal

Gynecologic oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr KURTZ Jean-Emmanuel

Tous les auteurs :
Bogani G, Moore KN, Ray-Coquard I, Lorusso D, Matulonis UA, Ledermann JA, González-Martín A, Kurtz JE, Pujade-Lauraine E, Scambia G, Caruso G, Raspagliesi F, Colombo N, Monk BJ

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39764856

Résumé

Therapeutic interventions for epithelial ovarian cancer (EOC) have increased greatly over the last decade but improvements outside of biomarker selected therapies have been limited. There remains a pressing need for more effective treatment options that can prolong survival and enhance the quality of life of patients with EOC. In contrast to the significant benefits of immunotherapy with immune checkpoint inhibitors (CPI) seen in many solid tumors, initial experience in EOC suggests limited efficacy of CPIs monotherapy.